Huang, M., Lou, Y., Pellissier, J., Burke, T., Liu, F. X., Xu, R., & Velcheti, V. (2017). Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. Pharmacoeconomics.

Huang, Min, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu, and Vamsidhar Velcheti. "Cost Effectiveness of Pembrolizumab Vs. Standard-of-Care Chemotherapy As First-Line Treatment for Metastatic NSCLC That Expresses High Levels of PD-L1 in the United States." Pharmacoeconomics 2017.

Huang, Min, et al. "Cost Effectiveness of Pembrolizumab Vs. Standard-of-Care Chemotherapy As First-Line Treatment for Metastatic NSCLC That Expresses High Levels of PD-L1 in the United States." Pharmacoeconomics 2017.